These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1291 related articles for article (PubMed ID: 11223449)

  • 1. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
    Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.
    Guérin M; Bruckert E; Dolphin PJ; Turpin G; Chapman MJ
    Arterioscler Thromb Vasc Biol; 1996 Jun; 16(6):763-72. PubMed ID: 8640404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VLDL-induced triglyceride accumulation in human macrophages is mediated by modulation of LPL lipolytic activity in the absence of change in LPL mass.
    Milosavljevic D; Kontush A; Griglio S; Le Naour G; Thillet J; Chapman MJ
    Biochim Biophys Acta; 2003 Feb; 1631(1):51-60. PubMed ID: 12573449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
    Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM
    Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
    Guerin M; Le Goff W; Frisdal E; Schneider S; Milosavljevic D; Bruckert E; Chapman MJ
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3738-46. PubMed ID: 12915663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans.
    Anber V; Millar JS; McConnell M; Shepherd J; Packard CJ
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2507-14. PubMed ID: 9409221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate.
    Farnier M; Perevozskaya I; Taggart WV; Kush D; Mitchel YB
    J Lipid Res; 2008 Dec; 49(12):2641-7. PubMed ID: 18669979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
    Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
    Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations.
    Srisawasdi P; Vanavanan S; Rochanawutanon M; Pornsuriyasak P; Tantrakul V; Kruthkul K; Kotani K
    Clin Biochem; 2013 Oct; 46(15):1509-15. PubMed ID: 23830843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.
    Chapman MJ; Guérin M; Bruckert E
    Eur Heart J; 1998 Feb; 19 Suppl A():A24-30. PubMed ID: 9519339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of mild to moderately elevated triglycerides on low density lipoprotein subfraction concentration and composition in healthy men with low high density lipoprotein cholesterol levels.
    Halle M; Berg A; Baumstark MW; König D; Huonker M; Keul Joseph
    Atherosclerosis; 1999 Mar; 143(1):185-92. PubMed ID: 10208494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ
    Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions.
    Packard CJ; Demant T; Stewart JP; Bedford D; Caslake MJ; Schwertfeger G; Bedynek A; Shepherd J; Seidel D
    J Lipid Res; 2000 Feb; 41(2):305-18. PubMed ID: 10681415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of bezafibrate treatment on the altered lipoprotein profiles in hypertriglyceridemic subjects.
    Norioka M; Suzuki M; Ryomoto K; Ikebuchi M; Harano Y
    J Atheroscler Thromb; 2000; 7(4):198-202. PubMed ID: 11521682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein composition in insulin-dependent diabetes mellitus with chronic renal failure: effect of kidney and pancreas transplantation.
    Hughes TA; Gaber AO; Amiri HS; Wang X; Elmer DS; Winsett RP; Hathaway DK; Hughes SM; Ghawji M
    Metabolism; 1994 Mar; 43(3):333-47. PubMed ID: 8139482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.